- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -
- Cash, cash equivalents, and marketable securities of $296.3...
Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits
NEW YORK, Aug....
ROCKVILLE, Md., Aug. 14, 2025 /PRNewswire/ -- Today, On Demand Pharmaceuticals (ODP) hosted senior officials from the U.S. Department of Health and Human Services...
New Jersey Department of Labor Commissioner Robert Asaro-Angelo, Assemblywoman Tennille McCoy, Plainsboro Township Mayor Edmund Yates, Middlesex County Board of Commissioners Director Ronald Rios,...
Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...
PARIS, Aug. 14, 2025 /PRNewswire/ -- Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for...
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...
Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...
New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment...
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —
— BRINSUPRI 10...
DELRAY BEACH, Fla., Aug. 12, 2025 /PRNewswire/ -- The report 'Hydrofluoric Acid Market by Grade , Application, and Region (Asia Pacific, North America, Europe,...
DELRAY BEACH, Fla., Aug. 12, 2025 /PRNewswire/ -- The report 'Hydrofluoric Acid Market by Grade , Application, and Region (Asia Pacific, North America, Europe,...